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At Risk for Huntington's Disease
HD is a genetically caused brain disorder that causes uncontrollable bodily movements and robs
people's ability to walk, talk, eat, and think. The final result is a slow, ugly death. Children of parents
with HD have a 50-50 chance of inheriting the disease. There is no cure or treatment.
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FRIDAY, JULY 24, 2015

Isis Pharmaceuticals launches historic clinical trial to
silence Huntington’s disease gene
Isis Pharmaceuticals, Inc., based in Carlsbad, CA, has launched its longawaited clinical trial to test a drug designed to attack Huntington’s disease
at its genetic roots.
In a July 21 press release, Isis said it had initiated a Phase I human clinical
study of ISIS-HTTRx, its compound aimed at diminishing the symptoms of
HD. HTTRx signifies a medication for HD. The disease is caused by a
defect in both the huntingtin gene and protein, which are symbolized by
the letters htt.
“ISIS- HTTRX is the first therapy to enter clinical development that is
designed to directly target the cause of the disease by reducing the
production of the protein responsible for HD,” the release stated.
In partnership with Roche, the Switzerland-based pharmaceutical giant
sharing costs of the typically expensive clinical trial, Isis thus becomes the
first entity to use a gene-silencing technique in the attempt to stop HD.
“Although the toxic protein produced from the huntingtin (HTT) gene in
HD patients has been a target of interest for many years, no therapies have
advanced to clinical trials to treat the underlying cause of the disease,”
Frank Bennett, Ph.D., Isis’s senior vice president of research, stated . “Our
antisense technology has enabled us to discover and develop ISIS-HTTRx,
the first therapeutic approach designed to treat the genetic cause of HD."
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Frank Bennett, Ph.D., of Isis Pharmaceuticals (photo by Dr. Ed Wild)
A ‘significant milestone’
HTTRx is an antisense oligonucleotide, an artificial strand of DNA created
by Isis to block the action of the RNA molecules that translate the
huntingtin genetic code to make the huntingtin protein.
Involving about 36 early-stage HD patients at about six sites in Europe and
Canada, the Phase I trial focuses on the safety and tolerability of HTTRx.
According to an Isis spokesperson, the sites will start recruiting
participants as early as in a few weeks.
Depending on the pace of recruitment, Phase I most likely will end in 2017.
If Phase I is successful, a larger Phase II trial to test efficacy likely would
take place in 2018. A successful Phase II trial would be followed by a Phase
III trial. Together all three phases of a clinical trial program typically take
at least five years.
Last August, scientists from Isis and CHDI Foundation, Inc., the nonprofit
virtual biotech firm that funded the early stages of the Isis research
starting in 2007, provided extensive details about the plans for the trial.
(Click here to read more.).
“The initial development of this antisense drug for Huntington’s disease
came out of a longstanding productive partnership between Isis and CHDI,
and its advancement now to clinical trial is testament to Isis’ perseverance
and scientific expertise,” CHDI president Robi Blumenstein stated in the
press release. “It’s exciting that therapeutic candidates grounded in the
biology of Huntington’s disease are finally making their way to clinical
trial.”
“The initiation of the ISIS-HTTRx study is a significant milestone in the
history of Huntington's disease research as this marks the first time a drug
designed specifically for Huntington's patients has transitioned into the
clinic,” George Yohrling, Ph.D., senior director for mission and scientific
affairs for the Huntington’s Disease Society of America (HDSA), wrote in
curehd.blogspot.com/2015/07/isis-pharmaceuticals-launches-historic.html
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an e-mail. “My hope is that this study not only shows that the drug is safe,
but serves as an informative beacon for all future huntingtin-lowering
trials.”
Martha Nance, M.D., the director of the HDSA Center of Excellence at
Hennepin County Medical Center in Minneapolis and a member of the
executive committee of the Huntington Study Group, said that “it would be
impossible to overstate the importance of this trial.”
“I am old enough to have grown up in the 1960s, swept up as a young child
with the excitement of space exploration, and I remember, almost as
clearly and importantly as the Apollo 11 mission that actually LANDED on
the moon, the Apollo 8 mission over Christmas 1968, during which
William Anders took the iconic picture of the earthrise over the moon,” Dr.
Nance wrote in an e-mail. “There were several more steps, several more
Apollo missions, before Neil Armstrong could jump off the ladder onto the
moon. The ISIS study is the HD equivalent of the Apollo 8 mission.”
LaVonne Goodman, M.D., the founder of Huntington's Disease Drug
Works, said that there are "high hopes and expectations" about the trial.
"We celebrate those individuals with HD, heroes who are selflessly
participating in this trial and all others, 'taking one for the team,'" she
wrote in an e-mail.
“We’re very enthusiastic about the drug,” Dr. Bennett said in a 2014
interview.
As he put it previously, Isis technology is like a “laser-guided missile” that
targets a specific, disease-causing messenger RNA and destroys it or takes
it out of the body “so that you don’t produce that messenger RNA.”
The Isis-Roche partnership
According to the press release, with the initiation of the clinical trial, Isis –
a small company – earned a $22 million milestone payment from Roche.
To date, Isis has earned $52 million in upfront and milestone payments
from the partnership. It can earn more as the project progresses, as well as
royalties on potential sales.
Roche can exercise the option to license ISIS- HTTRx from Isis through the
completion of the Phase 1 trial. If so, Roche will assume responsibility for
global development, the acquisition of regulatory approvals, and
marketing the drug.
The partnership is critical. Isis cannot alone afford to carry out a clinical
trial. Drugs usually cost hundreds of millions of dollars to develop.
According to the press release, Isis’s drug projects include 38 drugs aimed
at treating a wide range of diseases, among them cardiovascular disease,
metabolic disorders, cancer, and severe and rare diseases, including
neurological disorders such as HD.
A huge dose of hope
The announcement of the historic trial’s launch provides a huge dose of
hope for the HD community.
Since the discovery of the huntingtin gene in 1993, scientists have
published thousands of research papers on HD and identified hundreds of
potential “targets” for treatments.
In recent years, scientists and drug companies have initiated an increasing
number of clinical trials in the quest for effective treatments. However, to
date none has proven successful in halting the disease.
curehd.blogspot.com/2015/07/isis-pharmaceuticals-launches-historic.html
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A necessary leap
As seen in animal studies, the infusion of HTTRx into the brain has led to
the disappearance of the HD-like symptoms.
Scientists warn that it’s a still a huge leap from animals to humans when it
comes to testing drugs. Also, only about one in ten clinical trials results in
a drug reaching the market.
Earlier this year prominent HD specialist Bernhard Landwehrmeyer, M.D.,
Ph.D., cautioned that it could still take decades for the gene-silencing
approach to play an effective part in managing the disease.
“We should all be extremely excited and hopeful, but remember that there
is a lot of work ahead for researchers, doctors, patients, and families before
we will get to our moon, and no guarantee of success,” wrote Dr. Nance.
Nevertheless, the Isis-Roche trial is a major step. At a minimum, it will
help answer key questions about the gene-silencing approach.
If it is successful in ameliorating symptoms, it could mean the beginning of
the end of Huntington’s disease as a threat to the tens of thousands of
families affected worldwide.
***
Below see links to previous reports on Isis.
"Moving toward a potential treatment: Isis, CHDI researchers outline
upcoming Huntington's disease gene-silencing clinical trial"
"A key new ally in the search for Huntington's disease treatments"
"Quickening the pace towards a Huntington's disease gene-silencing
clinical trial: pharma giant Roche, Isis enter partnership"
"Designing the best drug possible to defeat Huntington's disease"
"Building a 'laser-guided missile' to attack Huntington's disease"
"Observing the cure in progress"
Also see coverage at HDBuzz by clicking here.
(Disclaimer: I hold a symbolic number of Isis shares.)
Posted by Gene Veritas at 8:15 AM
Labels: antisense oligonucleotide , CHDI , clinical trial , DNA , drug development ,
Frank Bennett , genetic , hope , huntingtin , Huntington's disease , Isis
Pharmaceuticals , ISIS-HTTRx , protein , RNA , Roche , symptoms , treatments

5 comments:
Anonymous said...
Awesome!
7:17 PM, July 26, 2015

Anonymous said...
Is it expensive treatment? I mean ISIS-HTTRx itself and
delivering into the spinal? I consider such type of cerement will
be refunded by the government.
4:09 AM, July 27, 2015
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Anonymous said...
Have you heard anything about using Vitamin B3 (Niacin) for
Huntington's Disease?
I came across an old article by the late Dr. Abram Hoffer (he
was a biochemist & psychiatrist I believe) from the 1970s
mentioning someone with HD who came to him. The patient
took Niacin and his neuro symptoms disappeared, something
like that??
I haven't seen anything else on that so I'm checking out various
blog posts etc
10:17 PM, September 02, 2015

Unknown said...
I am happy for this progress but sad to have to read about the
royalties to the compamny. In the end it makes it clear this is
still about corporate business, will HD families be able to afford
it?
2:31 PM, September 05, 2015

Jason said...
Why is it sad for them to earn royalties on the treatment? The
hard-working scientists that are developing this drug deserve to
be paid for their dedication. This is their job, they have families
to feed, mortgages and student loans to pay.
Sure, the drug will probably be expensive -- in large part
because the *trials* are so expensive to conduct, not simply
because people are greedy -- but that's why we have health
insurance. No individual or family can reasonably be expected
to pay for this kind of treatment from out-of-pocket, and no
treatment like this could realistically be developed
inexpensively enough for people to do so. That's why medical
insurance (or nationalized health care) exists.
11:22 PM, September 10, 2015
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